Filing Details

Accession Number:
0001127602-25-009283
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-03-12 18:41:26
Reporting Period:
2025-03-10
Filing Date:
2025-03-12
Accepted Time:
2025-03-12 18:41:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882095 Gilead Sciences Inc. GILD Biological Products, (No Disgnostic Substances) (2836) 943047598
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1310204 D Andrew Dickinson Gilead Sciences, Inc.
333 Lakeside Drive
Foster City CA 94404
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-03-10 4,916 $63.91 173,977 No 4 M Direct
Common Stock Acquisiton 2025-03-10 13,013 $63.91 186,990 No 4 M Direct
Common Stock Disposition 2025-03-10 4,916 $117.30 182,074 No 4 S Direct
Common Stock Disposition 2025-03-10 13,013 $118.50 169,061 No 4 S Direct
Common Stock Acquisiton 2025-03-10 7,968 $0.00 177,029 No 4 M Direct
Common Stock Disposition 2025-03-10 3,855 $117.21 173,174 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2025-03-10 4,916 $0.00 4,916 $63.91
Common Stock Non-qualified Stock Option (Right to Buy) Disposition 2025-03-10 13,013 $0.00 13,013 $63.91
Common Stock Restricted Stock Unit Disposition 2025-03-10 7,968 $0.00 7,968 $0.00
Common Stock Non-qualified Stock Option (Right to Buy) Acquisiton 2025-03-10 49,020 $0.00 49,020 $117.21
Common Stock Restricted Stock Unit Acquisiton 2025-03-10 11,090 $0.00 11,090 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
13,013 2031-03-10 No 4 M Direct
0 2031-03-10 No 4 M Direct
27,519 No 4 M Direct
49,020 2035-03-10 No 4 A Direct
38,609 No 4 A Direct
Footnotes
  1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
  2. Sale prices reported for the transactions reported here range from $116.97 to $117.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  3. Sale prices reported for the transactions reported here range from $118.00 to $118.80. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  4. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
  5. The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
  6. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.